<DOC>
	<DOC>NCT00568516</DOC>
	<brief_summary>To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer</brief_summary>
	<brief_title>Phase II Study of ASP3550 in Patients With Prostate Cancer</brief_title>
	<detailed_description>Two doses of ASP3550 were administered to patients with prostate cancer. The primary efficacy variable was the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Is a male patient with histologically proven prostate cancer (adenocarcinoma) of all stages Is a patient in whom endocrine treatment is indicated. Patients with rising serum PSA after having prostatectomy or radiotherapy performed with curative intention may be included Has a serum testosterone level above 1.5 ng/mL at screening Has an ECOG (Eastern Cooperative Oncology Group) P.S. (Performance Status) score of 0 to 2 Previous or present endocrine treatment for prostate cancer. However, patients who have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6 months and in whom prostatectomy or radiotherapy was terminated at least 6 months preceding Screening Visit may be included Is being treated with a 5Î±reductase inhibitor Is a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months Has concurrent or a history of severe asthma (defined as a need for daily treatment with inhalation steroids), anaphylactic reactions, severe urticaria and angioedema</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ASP3550</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostatic neoplasms</keyword>
</DOC>